10 Best Stocks Under $10 That Could Triple
On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, shared his views on small-cap stocks, which are projected to sustain their above-market performance as valuations stay...
Lexeo Therapeutics Inc. (LXEO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradigm Biocapital Advisors Senai Asefaw | 6,184,134 | $35,496,929 | +30% | 0.73% |
| 2. | RA Capital Management Peter Kolchinsky | 5,000,000 | $28,700,000 | 0.3% | |
| 3. | Vestal Point Capital Ryan Wilder | 4,475,000 | $25,686,500 | 0.72% | |
| 4. | Citadel Investment Group Ken Griffin | 3,834,999 | $22,012,895 | +2% | 0% |
| 5. | OrbiMed Advisors Samuel Isaly | 3,602,450 | $20,678,063 | +70% | 0.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.99 | 15,000 | $104,851.50 | 30,627 | 2024-11-25 | Filing | |
| $11.00 | 454,545 | $4,999,995.00 | 2,157,623 | 2023-11-07 | Filing | |
| $11.00 | 227,272 | $2,499,992.00 | 1,835,959 | 2023-11-07 | Filing | |
| $11.00 | 454,545 | $4,999,995.00 | 2,567,100 | 2023-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.49 | 4,641 | $20,838.09 | 97,024 | 2026-07-01 | Filing | |
| $4.48 | 4,666 | $20,903.68 | 137,482 | 2026-07-01 | Filing | |
| $4.42 | 22,306 | $98,592.52 | 82,194 | 2026-07-01 | Filing | |
| $4.48 | 25,947 | $116,242.56 | 377,817 | 2026-07-01 | Filing | |
| $5.07 | 1,302 | $6,606.35 | 130,088 | 2026-05-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 265,697 | $1,236,820 | 0.04% | |
| 2. | 247 | $1,150 | 0% | |
| 3. | 178 | $829 | 0% | |
| 4. | 0 | $0 | 0% |
News See All
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?
TheFly reported on June 25 that JPMorgan adjusted its price target for LXEO, lowering it to $9 from $12 while maintaining an Overweight rating on the shares.
8 Best Up and Coming Pharmaceutical Stocks to Buy Now
Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks.
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program
TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc.
13 Best Get Rich Fast Stocks to Buy Right Now
In today's fast-paced world, everyone is prioritising investments that have both high and relatively quick returns.
Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim's Stock Picks with Huge Upside Potential
Lexeo Therapeutics (NASDAQ:LXEO) is one of billionaire Daniel Sundheim’s stock picks with huge upside potential.
Billionaire Daniel Sundheim's 10 Stocks Picks with Huge Upside Potential
The upward momentum in the equity market is likely to continue heading into the year-end. It is a stance held by major investment banks in response to the economy and consumers showing resilience.
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the hot stocks to buy with huge upside potential. On October 21, H.C.